文献速递头颈外科

18F-FDG PET/CT 在头颈癌放化疗后持续性颈部淋巴结病患者管理中的作用

Role of 18F-FDG PET/CT in the management of head and neck cancer patients with persistent cervical lymphadenopathy following chemoradiation.
PubMed 文献 · Head Neck · 2024-07-16

回顾性分析2010至2022年一家三级医疗中心因头颈鳞状细胞癌接受根治性同步放化疗后出现持续性颈部淋巴结病的患者,描述基于治疗后 PET/CT 结果的管理与结局。约62%患者保守管理,27.0%行颈清扫;PET阳性者较PET阴性者更常行颈清扫(p=0.042)。PET/CT 检测颈部残留病的阳性预测值和阴性预测值分别为48.0%和73.7%。

要点

  • 放化疗后持续性颈部淋巴结病患者中约62%保守管理,27.0%行颈清扫。
  • PET阳性患者较PET阴性患者更常行颈清扫(p=0.042)。
  • PET/CT 检测颈部残留病的阳性预测值48.0%、阴性预测值73.7%。

核心结论

  • 在放化疗后持续性颈部淋巴结病的头颈鳞状细胞癌患者中,PET/CT 检测颈部残留病的阳性预测值和阴性预测值低于其他研究中报告的有或无持续性淋巴结病的头颈鳞状细胞癌患者。

研究设计与样本

  • 回顾性病历审查,纳入2010至2022年一家三级医疗中心因头颈鳞状细胞癌接受根治性同步放化疗后出现持续性颈部淋巴结病的所有患者。

主要发现

  • 约62%患者保守管理,27.0%行颈清扫。
  • PET阳性患者较PET阴性患者更常行颈清扫(p=0.042)。
  • PET/CT 检测颈部残留病的阳性预测值为48.0%,阴性预测值为73.7%。

关键数值与推荐

  • PET/CT 检测颈部残留病的阳性预测值48.0%,阴性预测值73.7%。
  • PET阳性患者较PET阴性患者更常行颈清扫(p=0.042)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aim to describe the management and outcomes of patients with persistent lymphadenopathy (LAD) after primary chemoradiation for head and neck squamous cell carcinoma (HNSCC) based on post-treatment PET/CT results. METHODS: Retrospective chart review was conducted of all patients who underwent primary concurrent chemoradiation for HNSCC at a tertiary care center from 2010 to 2022 and had persistent post-treatment LAD. RESULTS: Nearly 62% of patients were managed conservatively, and 27.0% underwent neck dissection. PET-positive patients were more likely to undergo neck dissection than PET-negative patients (p = 0.042). Positive predictive value (PPV) and negative predictive values (NPV) of PET/CT in detecting residual disease in the neck were 48.0% and 73.7%, respectively. CONCLUSIONS: PPV and NPV of PET/CT for detecting residual neck disease in patients with post-treatment LAD was lower than those of HNSCC patients with and without persistent LAD reported in other studies.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Sharma A, Quereshy H, Cabrera CI, et al. Role of 18F-FDG PET/CT in the management of head and neck cancer patients with persistent cervical lymphadenopathy following chemoradiation. Head Neck. 2024. PMID: 39011903. doi:10.1002/hed.27872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。